Search
01/09/2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Mysler, E, Ignatenko, S, Gordienko, A, Cort s-Hern ndez, J, Agmon-Levin, N, Narongroeknawin, P, Romanowska-Prochnicka, K, Shen, N, Cifersk , H, Kodera, M, Wei, JCC, Leszczynski, P, Lan, JL, Wojciechowski, R, Tarr, T, Vishneva, E, Chen, YH, Kaneko, Y, Finzel, S, Hoi, A, Okada, M, Koolvisoot, A, Lee, SS, Dai, L, Kaneko, H, Rojkovich, B, Sun, LY, Zotkin, E, Viallard, JF, Magallares, BP, Sengupta, T, Sips, C, Lau, C, Avrameas, A, Oliver, SJ. Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease
Zhang, YL, Tedeschi, S, Abhishek, A, Hensey, O, Grossberg, D, Cai, K, Shea, B, Singh, J, Christensen, R, Serban, T, Cipolletta, E, Parperis, K, D az, C, McCarthy, G, Becce, F, Gheita, TA, Sirotti, S, Christiansen, SN, Tarancon, LC, Stamp, L, Abdel-Fattah, YH, Pascart, T, Filippou, G, Hong, LE, FitzGerald, J, Dalbeth, N. Delphi Survey to Establish Consensus on the OMERACT Core Domain Set for Long-Term Studies of Calcium Pyrophosphate Deposition Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Effectiveness of Rituximab in IgG4 Related Disease
Lopez-Gutierrez, F, Loricera, J, Hormigos, C, Nu ez, DF, Rodriguez-Laguna, M, Albarado, PM, G mez, MLI, Corominas, H, Silva-D az, M, Arribas, GG, Garcia-Aparicio, A, Urgelles, JF, Casafont-Sole, I, Calabuig, PM, Castaneda, E, Merino, C, Zas, R, Molina-Collada, J, Melero-Gonzalez, RB, Galindez-Agirregoikoa, E, Hern ndez-Mart n, A, Pantoja, L, Abascal, IB, Jovani, V, Valls-Pascual, E, V zquez, NM, Gallego-Flores, A, Ra a, NC, Veroz, R, Andres, M, Casta eda, S, Blanco-Alonso, R. Effectiveness of Rituximab in IgG4 Related Disease. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Guerrero, MR, Moriano, C, Santos, CS, Herranz, LS, Garcia, JJ, Barranco, IC, Alvarez, ED. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
De Silva, C, D az, C, Gamble, G, Horne, A, Doyle, A, Stamp, L, Dalbeth, N. Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).
01/09/2024
Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
Quevedo-Rodr guez, A, Otero-Varela, L, S nchez-Alonso, F, P rez-Vera, Y, Manero-Ruiz, J, Campos-Fern ndez, C, Manrique-Arija, S, Vela-Casasempere, P, Mera-Varela, A, D az, C, Movasat, A, Garcia-Magallon, B, Ros-Vilamaj , I, Perez-Garcia, C, Castrejon, I. Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases. Arthritis & Rheumatology. 2024; 76DOI:. PMID:. IF:10.900(Q1/1D).